MedTrace Logo

Safety/Tolerability, PK and Efficacy of IMB071703 Injection in Patients With Advanced Solid Tumors

NCT06292858 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2024-03-05

No results posted yet for this study

Summary

A Phase Ia Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Preliminary Efficacy of IMB071703 Injection in Subjects with Recurrent or Metastatic，Advanced Solid Tumors

Conditions

  • Recurrent or Metastatic, Advanced Solid Tumors

Interventions

DRUG

IMB071703 injection

Intratumoral injection

Sponsors & Collaborators

  • Beijng Immunoah Pharma Tech Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-24
Primary Completion
2025-04-30
Completion
2025-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06292858 on ClinicalTrials.gov